These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 32782782)
1. Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. Dupuis M; Shen Y; Curcio C; Meis JM; Wang WL; Amini B; Rhines L; Reuther J; Roy A; Fisher KE; Conley AP; Andrew Livingston J Clin Sarcoma Res; 2020; 10():14. PubMed ID: 32782782 [TBL] [Abstract][Full Text] [Related]
2. An addition to the evolving spectrum of lipofibromatosis and lipofibromatosis-like neural tumor: Molecular findings in an unusual phenotype aid in accurate classification. Malik F; Santiago T; Newman S; McCarville B; Pappo AS; Clay MR Pathol Res Pract; 2020 Jun; 216(6):152942. PubMed ID: 32299759 [TBL] [Abstract][Full Text] [Related]
3. LMNA-NTRK1 rearranged mesenchymal tumor (lipofibromatosis-like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. Panse G; Reisenbichler E; Snuderl M; Wang WL; Laskin W; Jour G J Cutan Pathol; 2021 Feb; 48(2):290-294. PubMed ID: 32519338 [TBL] [Abstract][Full Text] [Related]
4. Unusual Presentation of Lipofibromatosis-Like Neural Tumor in an Adult: A Case Report. Zarak MS; Sliker T; Javadi T; Ullah A; Heneidi SG; Biddinger P; Savage NM; Homlar K; Clarence J; White J Saudi J Med Med Sci; 2021; 9(3):267-270. PubMed ID: 34667475 [TBL] [Abstract][Full Text] [Related]
5. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. Antonescu CR; Dickson BC; Swanson D; Zhang L; Sung YS; Kao YC; Chang WC; Ran L; Pappo A; Bahrami A; Chi P; Fletcher CD Am J Surg Pathol; 2019 Oct; 43(10):1384-1391. PubMed ID: 31219820 [TBL] [Abstract][Full Text] [Related]
6. Lipofibromatosis-like neural tumor: Case report of a unique infantile presentation. Bartenstein DW; Coe TM; Gordon SC; Friedmann AM; Senna MM; Kelleher CM; Antonescu CR; Nazarian RM; Hawryluk EB JAAD Case Rep; 2018 Mar; 4(2):185-188. PubMed ID: 29892662 [TBL] [Abstract][Full Text] [Related]
7. Generating in vitro models of NTRK-fusion mesenchymal neoplasia as tools for investigating kinase oncogenic activation and response to targeted therapy. Vanoli F; Herviou L; Tsuda Y; Sung P; Xie Z; Fishinevich E; Min SS; Mallen W; de Wardin HT; Zhang Y; Jasin M; Antonescu CR Oncogenesis; 2023 Feb; 12(1):8. PubMed ID: 36801905 [TBL] [Abstract][Full Text] [Related]
8. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related]
9. Activity of Entrectinib in a Patient With the First Reported Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225 [TBL] [Abstract][Full Text] [Related]